ESRRA

Across TCGA pan-cancer cohorts, ESRRA RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ESRRA’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ESRRA RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ESRRA is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

LIHC, THCA, and KICH are the cancer types where ESRRA tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ESRRA RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.051	<.001	8	view →
THCA	All	All	−0.371	<.001	8	view →
KICH	Female	III,IV	+1.533	<.001	7	view →
UCEC	All	All	+0.979	<.001	6	view →
LUSC	All	All	+0.370	.001	5	view →
STAD	All	II,III,IV	+0.726	.003	4	view →
KIRC	Male	All	−0.422	<.001	4	view →
BLCA	Male	All	+0.532	.007	3	view →
KIRP	All	All	−0.354	.003	3	view →
CHOL	Female	All	+1.700	<.001	2	view →
READ	All	II,III,IV	−0.872	.044	1	view →
ESCA	Female	All	+0.760	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ESRRA–LIHC

Open the LIHC breakdown →